Hims & Hers Health Inc., one of the largest telehealth companies operating in the peptide compounding space, is scheduled to meet with White House budget officials on Friday, October 23, 2026, to discuss the FDA’s reported plan to create an interim pathway for state-licensed pharmacies to compound certain peptides currently ineligible for 503A compounding.
The meeting comes as the Office of Management and Budget (OMB) continues its review of the HHS/FDA document titled “Interim Access Policy for Compounding Using Certain Peptides” (RIN 0910-ZD94). The engagement places Hims & Hers as a direct industry participant in the federal policy development process ahead of any potential regulatory action.
While no final decision has been made on the interim access framework, the meeting signals that major telehealth operators are actively seeking to shape the rules that could govern their ability to offer compounded peptide therapies.
What happened
Hims & Hers is set to meet with White House budget officials on October 23 to discuss the FDA’s interim peptide access policy. The policy under review reportedly aims to establish a pathway allowing state-licensed pharmacies to compound certain unapproved wellness peptides that are not currently eligible for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.
The OMB is reviewing the proposed policy document, identified by regulatory tracking number RIN 0910-ZD94. No final decision on the policy has been made.
Why it matters
A major telehealth operator engaging directly with the White House on a pending peptide policy indicates that the industry is actively working to influence the final terms of any interim access framework. The outcome of discussions like this could affect what patient protections, reporting requirements, or compounding conditions are included in an eventual policy.
Several groups have a stake in the outcome:
- Telehealth companies offering compounded peptides, which could face new operational requirements or gain clarity on permissible compounds.
- Compounding pharmacies operating under 503A or 503B frameworks, which may see changes to which peptides they are permitted to compound.
- Consumers accessing peptide therapies through telehealth platforms, whose access and options could shift depending on the final policy.
- Peptide ingredient suppliers, whose demand and compliance landscape could be affected by any new compounding pathway.
The policy remains under review, and no interim access framework has been finalized.
What to watch next
- Whether the OMB completes its review of RIN 0910-ZD94 and the document moves toward publication.
- Whether other telehealth companies, pharmacy groups, or patient advocacy organizations also engage with OMB or FDA during the review period.
- What specific compounding conditions, reporting requirements, or peptide eligibility criteria appear in any published interim policy.
- Whether the final policy differs from what was discussed in the October 23 meeting.
Sources
Industry information only. Not medical or legal advice.
